Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $6.06 Million - $9.97 Million
-2,504,493 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$3.11 - $4.61 $6.93 Million - $10.3 Million
-2,228,830 Reduced 47.09%
2,504,493 $9.74 Million
Q3 2021

Nov 15, 2021

SELL
$2.65 - $4.62 $3.3 Million - $5.75 Million
-1,245,032 Reduced 20.83%
4,733,323 $20.3 Million
Q3 2020

Nov 16, 2020

SELL
$1.75 - $6.2 $1.56 Million - $5.52 Million
-890,926 Reduced 12.97%
5,978,355 $18.7 Million
Q1 2020

May 15, 2020

BUY
$1.01 - $3.42 $1.21 Million - $4.11 Million
1,202,527 Added 21.22%
6,869,281 $6.94 Million
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $90,294 - $299,944
103,787 Added 1.87%
5,666,754 $15.8 Million
Q3 2019

Nov 14, 2019

BUY
$1.34 - $2.4 $40,031 - $71,697
29,874 Added 0.54%
5,562,967 $8.48 Million
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $33,390 - $101,542
22,870 Added 0.42%
5,533,093 $11.5 Million
Q1 2019

May 15, 2019

BUY
$3.41 - $4.57 $4 Million - $5.37 Million
1,174,477 Added 27.09%
5,510,223 $19.7 Million
Q4 2018

Feb 14, 2019

BUY
$3.5 - $9.66 $877,947 - $2.42 Million
250,842 Added 6.14%
4,335,746 $16.6 Million
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $8.48 Million - $13.3 Million
-1,080,595 Reduced 20.92%
4,084,904 $38.6 Million
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $69,420 - $102,047
13,884 Added 0.27%
5,165,499 $37.7 Million
Q4 2017

Feb 14, 2018

SELL
$4.45 - $7.7 $510,259 - $882,920
-114,665 Reduced 2.18%
5,151,615 $26 Million
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $17.9 Million - $36.9 Million
5,266,280
5,266,280 $32.7 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Rtw Investments, LP Portfolio

Follow Rtw Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Rtw Investments, LP with notifications on news.